Menopausal Hormones and Sympathetic Activation

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age40-58
SponsorUniversity of Delaware

About this trial

The purpose of this study is to understand how changes in menopausal hormones like estradiol and follicle-stimulating hormone (FSH) impact sympathetic nervous system function. To do so, the investigators will use a medication to control the production of estradiol and FSH, and in some participants, add-back estradiol to isolate its effects. The investigators will measure sympathetic activation centrally (in the brain using MRI), peripherally in the nervous system, and also examine adrenergic receptor mediated control of vascular function.

Eligibility criteria

Qualifiers

Perimenopausal (based on changes in menstrual cycle)

Ages 40-58 years

Disqualifiers

History of CVD, blood clots, stroke

History of Cancer

History of Liver or Kidney disease

History of Neurological disease

Trial design

Treatments tested in this trial

  • Estrogen
  • Placebo

Treatment groups

80 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators